Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ovid Therapeutics Q4 2023 GAAP EPS $(0.220) Misses $(0.100) Estimate, Sales $141.562K Beat $56.500K Estimate

Author: Benzinga Newsdesk | March 08, 2024 09:04am
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.220) per share which missed the analyst consensus estimate of $(0.100) by 120 percent. The company reported quarterly sales of $141.562 thousand which beat the analyst consensus estimate of $56.500 thousand by 150.55 percent. This is a 205.88 percent increase over sales of $46.280 thousand the same period last year.

Posted In: OVID


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist